Altimmune ALT
$2.08 +$0.11 (+5.58%)
Market closed · Nov 6, 8:10 pm ET · Last extended-hours $2.07 -0.48%
Open$1.97
Prev close$1.97
Day range$1.95 – $2.10
Volume2.77M
Market cap$404.60M
P/E (TTM)–
Dividend yield–
ALT Stock News
Headlines matching Altimmune or the ALT ticker, most recent first.
- ALT Co. Executive to Boost Stake With Gifted Shares
- TRALUCENT ASSET MANAGEMENT INC. GLOBAL ALT (LONG/SHORT) EQUITY FUND: FINAL FUND FACTS FR
- TRALUCENT ASSET MANAGEMENT INC. GLOBAL ALT (LONG/SHORT) EQUITY FUND: FINAL FUND FACTS EN
- TRALUCENT ASSET MANAGEMENT INC. GLOBAL ALT (LONG/SHORT) EQUITY FUND: FINAL ETF FACTS EN
- TRALUCENT ASSET MANAGEMENT INC. GLOBAL ALT (LONG/SHORT) EQUITY FUND: FINAL ETF FACTS FR
- Evercore Maintains Altimmune(ALT.US) With Buy Rating, Cuts Target Price to $17 Negative
- ALT Co., Ltd. Calls and Cancels Portion of 7th Convertible Bond Issuance
- GLOBAL X INVESTMENTS CANADA INC. BETAPRO -3X NASDAQ-100 DL LEV ALT ETF: INTERIM MANAGEMENT REPORT OF FUND PERFORMANCE FR
- GLOBAL X INVESTMENTS CANADA INC. BETAPRO -3X NASDAQ-100 DL LEV ALT ETF: INTERIM MANAGEMENT REPORT OF FUND PERFORMANCE EN
- H.C. Wainwright Maintains Altimmune(ALT.US) With Buy Rating, Maintains Target Price $20
- Barclays Maintains Altimmune(ALT.US) With Buy Rating, Maintains Target Price $20
- William Blair Maintains Altimmune(ALT.US) With Hold Rating
- A Quick Look at Today's Ratings for Altimmune(ALT.US), With a Forecast Between $10 to $20
- Truist Financial Maintains Altimmune(ALT.US) With Buy Rating
- H.C. Wainwright Sticks to Their Buy Rating for Altimmune (ALT)
No comments yet — be the first to weigh in on ALT.